A Trial of Mindfulness Meditation for Chronic Insomnia (MMI)
Primary Purpose
Insomnia
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Mindfulness Meditation
Sponsored by
About this trial
This is an interventional prevention trial for Insomnia
Eligibility Criteria
Inclusion Criteria:
- Over the age of 18
- Meet the diagnostic criteria for an insomnia disorder. Defined as difficulty initiating or maintaining sleep despite adequate opportunity, with at least one symptom of an associated daytime impairment. Additional quantitative insomnia criteria following research recommendations include frequency (defined as sleep onset latency (SOL) or wake after sleep onset (WASO) > 30 minutes at least 3 nights per week and for chronicity, defined as symptoms lasting > 6 months.
- Have access to an iOS or Android smartphone or a desktop computer with Internet access
- Participants will be required to sign an informed consent form
Exclusion Criteria:
- Uncontrolled medical condition suspected to interfere with sleep or requiring immediate treatment outside of the study
- Uncontrolled psychiatric conditions requiring immediate treatment outside of the study, including current major depressive episode
- Comorbid sleep disorders including obstructive sleep apnea
- Current use of hypnotic or sedating medications for the purpose of insomnia
- Inadequate proficiency in English to complete the protocol
- Participation in other trials concurrently
- Regular meditation practice defined as equal to or more than 2x weekly for the past 30 days
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Experimental (Mindfulness)
Control (Sleep Advice)
Arm Description
This arm will receive mindfulness-based interventions through a mobile application
This is the control arm that will receive usual care
Outcomes
Primary Outcome Measures
Change in Insomnia Severity (Insomnia Severity Index)
Insomnia Severity Index (ISI): The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score. This will be administered at baseline, after 8-weeks and at a 3 and 6-month follow-up. The index will be sent to by post and. It will take approximately 5 minutes to complete.
Change in Actigraphy determined wake time (TWT)
Actigraphy: Sleep onset latency (SOL) and wake after sleep onset (WASO) will be determined using wrist actigraphy. Participants will be provided with an actiwatch during the screening interview conducted at the beginning of the study. The actiwatch will be worn on the non-dominant arm 24 hours a day, except for while bathing, during the 2-week screening period. Additionally, the actiwatch will be worn for one week after the 8-week intervention and for one week prior to the 3 and 6-month follow-up. Participants will send the actiwatch to the investigator by post after each measurement period. The actiwatch will be sent to participants by post before the next measurement point; apart from the first time point where the participant will be given the actiwatch.
Secondary Outcome Measures
Review of mobile-based mindfulness meditation application for insomnia
Review of use of the mobile application and ascertain it's validity for use within this demographic of patients. The review will be performed using usage of the application by participants over the trial period.
Mindfulness (CAMS-R)
Mindfulness Inventory (CAMS-R): The CAMS-R will be administered at baseline, after 8-weeks and at a 3 and 6-month follow-up. The inventory will be sent to participants by post. It will take approximately 5 minutes to complete.
Full Information
NCT ID
NCT03337061
First Posted
October 27, 2017
Last Updated
February 14, 2020
Sponsor
Guy's and St Thomas' NHS Foundation Trust
1. Study Identification
Unique Protocol Identification Number
NCT03337061
Brief Title
A Trial of Mindfulness Meditation for Chronic Insomnia
Acronym
MMI
Official Title
A Trial of Mindfulness Meditation for Chronic Insomnia
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Study never started - halted by funder
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
August 1, 2018 (Actual)
Study Completion Date
August 1, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Guy's and St Thomas' NHS Foundation Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To evaluate the efficacy of mediation therapies on measures of sleep and arousal for people with chronic insomnia and with this the viability of smartphone delivered meditation based approaches at a population level.
Detailed Description
Sleep complaints are amongst the commonest in medical practice, and insomnia, the commonest of these affecting transiently 1/3 of the population at some point in the year and 1/3 of this population that is 1 in 10 persisting as chronic insomnia. There are significant consequences on the quality of life for individuals and significant economic burden for society.
Insomnia disorder is characterized as persistent difficulty in falling or staying asleep with resulting daytime dysfunction. Once physical and psychiatric causes have been excluded, current treatment guidelines include pharmacological and behavioural approaches. Hypnotic therapy will reduce sleep latency and increase total sleep time, but there are concerns about drug dependency and side effects (residual day time sleepiness and road traffic accidents and impaired balance). Behavioural treatment (CBTi) has been shown to be effective, but availability is scarce and less than 50% of patients achieve full remission, making alternative approaches desirable.
To optimize availability and to improve outcomes, approaches have included group sessions, single treatment sessions and internet sessions, but these are still limited in the NHS by availability of resources or by expense. Mindfulness meditation, focused non-judgmental awareness and attention on the present moment experience, can promote calmness and relaxation. Several health benefits have been shown across stress related conditions, including sleep disturbance, and its universal availability and ease of application make it an attractive alternative to conventional CBTi.
A randomized controlled trial compared Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Therapy for Insomnia (MBTI), and Self-monitoring (SM) in the treatment of chronic insomnia . Results indicate that those receiving mindfulness-based interventions (MBSR or MBTI) had significant reductions in total wake time and pre-sleep arousal from baseline-to-post compared to SM. The study concluded that mindfulness meditation appears to be a viable treatment option for adults with chronic insomnia and could provide an alternative to traditional treatments for insomnia.
A recent meta-analysis of 6 randomised controlled trials demonstrated that mindfulness meditation may contribute to improving sleep in subjects with insomnia compared to a control group. Specifically, mindfulness meditation was found to significantly reduce total wake time, sleep onset latency and sleep quality .
The present study builds upon this work, using a small-scale randomized controlled trial to gather preliminary evidence for the treatment efficacy of a brief mindfulness intervention delivered through a mobile application. Headspace (www.headspace.com) mindfulness app will be used to deliver the meditation content. Headspace currently has over 7 million users worldwide and was recently rated in a systematic review as being the highest quality mindfulness app on the market . Participants are adults with insomnia recruited through a sleep centre, recruited for management of their insomnia.
The potential risks of the study are low, as participants will be exposed to a low dose of mindfulness (10 minutes daily). Adverse effects of meditation have been reported in people with a predisposition to psychiatric illness that underwent extensive mindfulness training, such as a 10-day silent retreat. Negative effects have not been reported from 8-week mindfulness interventions. The benefits from this study include improvement in or resolution of insomnia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Experimental (Mindfulness)
Arm Type
Experimental
Arm Description
This arm will receive mindfulness-based interventions through a mobile application
Arm Title
Control (Sleep Advice)
Arm Type
No Intervention
Arm Description
This is the control arm that will receive usual care
Intervention Type
Other
Intervention Name(s)
Mindfulness Meditation
Intervention Description
Mindfulness Meditation delivered through a mobile application
Primary Outcome Measure Information:
Title
Change in Insomnia Severity (Insomnia Severity Index)
Description
Insomnia Severity Index (ISI): The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score. This will be administered at baseline, after 8-weeks and at a 3 and 6-month follow-up. The index will be sent to by post and. It will take approximately 5 minutes to complete.
Time Frame
8 weeks, 3 and 6 month follow-up
Title
Change in Actigraphy determined wake time (TWT)
Description
Actigraphy: Sleep onset latency (SOL) and wake after sleep onset (WASO) will be determined using wrist actigraphy. Participants will be provided with an actiwatch during the screening interview conducted at the beginning of the study. The actiwatch will be worn on the non-dominant arm 24 hours a day, except for while bathing, during the 2-week screening period. Additionally, the actiwatch will be worn for one week after the 8-week intervention and for one week prior to the 3 and 6-month follow-up. Participants will send the actiwatch to the investigator by post after each measurement period. The actiwatch will be sent to participants by post before the next measurement point; apart from the first time point where the participant will be given the actiwatch.
Time Frame
2-week screening, 8-week intervention, 3 and 6-month follow-up
Secondary Outcome Measure Information:
Title
Review of mobile-based mindfulness meditation application for insomnia
Description
Review of use of the mobile application and ascertain it's validity for use within this demographic of patients. The review will be performed using usage of the application by participants over the trial period.
Time Frame
6 months
Title
Mindfulness (CAMS-R)
Description
Mindfulness Inventory (CAMS-R): The CAMS-R will be administered at baseline, after 8-weeks and at a 3 and 6-month follow-up. The inventory will be sent to participants by post. It will take approximately 5 minutes to complete.
Time Frame
Baseline, 8-weeks, 3 and 6-month follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Over the age of 18
Meet the diagnostic criteria for an insomnia disorder. Defined as difficulty initiating or maintaining sleep despite adequate opportunity, with at least one symptom of an associated daytime impairment. Additional quantitative insomnia criteria following research recommendations include frequency (defined as sleep onset latency (SOL) or wake after sleep onset (WASO) > 30 minutes at least 3 nights per week and for chronicity, defined as symptoms lasting > 6 months.
Have access to an iOS or Android smartphone or a desktop computer with Internet access
Participants will be required to sign an informed consent form
Exclusion Criteria:
Uncontrolled medical condition suspected to interfere with sleep or requiring immediate treatment outside of the study
Uncontrolled psychiatric conditions requiring immediate treatment outside of the study, including current major depressive episode
Comorbid sleep disorders including obstructive sleep apnea
Current use of hypnotic or sedating medications for the purpose of insomnia
Inadequate proficiency in English to complete the protocol
Participation in other trials concurrently
Regular meditation practice defined as equal to or more than 2x weekly for the past 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicholas Hart, MD
Organizational Affiliation
Guys and St Thomas NHS Foundation Trust
Official's Role
Study Chair
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Trial of Mindfulness Meditation for Chronic Insomnia
We'll reach out to this number within 24 hrs